In-hospital mortality of intermittent vs daily antitubercular regimen in patients with meningeal tuberculosis--a retrospective study

Indian J Tuberc. 2012 Jan;59(1):6-11.

Abstract

Introduction: The Revised National Tuberculosis Control Programme (RNTCP), the State-run Tuberculosis Control Initiative of the Government of India, recommends intermittent thrice a week Directly Observed Treatment Short course (DOTS) both during intensive phase and continuation phase for a total of nine months for tubercular meningitis. However, most recent guidelines recommend daily regimen.

Objective: Assessment of the in-hospital mortality in patients with meningeal tuberculosis.

Material and methods: We retrospectively analyzed the data of patients (n = 98) admitted with a diagnosis of meningeal tuberculosis from January 1st 2006 to December 31st 2009 in a tertiary care centre in South India. Thwaites index score of four or less was used for diagnosis of meningeal tuberculosis which is a weighted diagnostic index score for dichotomised clinical variables including age, blood white cell count, duration of illness, CSF total white cell count, and CSF neutrophil percentage. We compared in-hospital treatment outcome of patients on thrice weekly intermittent DOTS regimen with daily regimen patients.

Results: The inhospital mortality was same (27%) in the two treatment regimens (p 0.944). However, there was less incidence of hepatic dysfunction in the intermittent DOTS regimen, even though it was not statistically significant (p 0.148).

Conclusions: In the short-term, both regimens have similar mortality outcomes and no statistically significant difference in hepatic dysfunction during the hospital stay.

MeSH terms

  • Adult
  • Antitubercular Agents / administration & dosage*
  • Chi-Square Distribution
  • Comorbidity
  • Directly Observed Therapy
  • Female
  • Hospital Mortality*
  • Humans
  • India / epidemiology
  • Male
  • Retrospective Studies
  • Severity of Illness Index
  • Tuberculosis, Meningeal / drug therapy*
  • Tuberculosis, Meningeal / mortality*

Substances

  • Antitubercular Agents